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Suicide Attempt with High Dose Long Acting 
Methylphenidate Ingestion: A Case Presentation 
Handan Ozek Erkuran1, Burcu Cakaloz2, Ozlem Onen1, Ayse Kutlu1
ABS TRACT:
Suicide attempt with high dose long acting methylphenidate ingestion: a case 
presentation 
Attention Deficit and Hyperactivity Disorder (ADHD) is among the most commonly encountered 
neurodevelopmental disorders in childhood with its reported worldwide prevalance as 5%. Among the 
recommended treatment regimens as stimulants, the most frequently advised ones are methylphenidate 
(MPH) preparates. Among long acting MPH preparates, the form that contains an osmotic release oral system 
(MPH-OROS) is frequently used in clinical practice. Studies about risks, causes and outcomes regarding high 
dose MPH intake and effects of high dose MPH preparates in humans are limited. This article presents the 
clinical picture of a 12 year old boy who attempted suicide by ingesting 15 tablets of 36- mg MPH OROS. 
Exposure to an overdose of MPH-OROS exhibited acute sympathomimetic toxicity but no life-threatening 
symptoms in this patient. This case report might suggest that higher doses of MPH-OROS could be tolerated 
well under fine clinical observation and management; although more larger scale studies in this field would 
be required.
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INTRODUCTION
Attention Deficit Hyperactivity Disorder (ADHD) is 
among the most commonly encountered 
neurodevelopmental disorders in childhood with 
reported worldwide prevalance as 5%1. Current 
practice parameters underline importance of 
utilizing combination of educational, behavioral, 
a n d  f a m i l i a l  a p p r o a c h e s  a l o n g  w i t h 
pharmacological interventions as treatment 
modalities2. Stimulants are the most common type 
of medications used for the ADHD and 
methylphenidate (MPH) preparations are the most 
frequently prescribed ones3. Among long acting 
MPH preparations, the form that contains osmotic 
release oral system (MPH-OROS) is frequently used 
in clinical practice since is said to remain efficient 
for 10-12 hours and does not require multiple 
dosing throughout the day4. MPH is reported to 
have broad margin of safety and tolerated well4. 
Studies about risks, causes and outcomes regarding 
high dose MPH intake and effects of high dose MPH 
in humans are limited5,6. Mechanism of MPH 
toxicity is primarily related to excessive extracellular 
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dopamine and norepinephrine. Symptoms include 
headache, abnormal movements, rigidity, mood 
a n d  b e h a v i o r  c h a n g e s,  h a l l u c i n a t i o n s, 
hypertension, tachycardia, chest pain, and 
vomiting7. This article presents clinical picture of a 
12 year old boy who attempted suicide by ingesting 
15 tablets of 36 mg MPH OROS.
CASE PRESENTATION
The case was a 12 year old 6th grader boy. He was 
diagnosed with ADHD when he was 7 years old and 
had been on stimulants since then in altering doses. 
Patient had no history of other psychiatric or 
neurological conditions, substance abuse or suicide 
attempts. His developmental history and intellectual 
capacity were within normal limits and was doing 
fine academically. In his family; his brother was 
diagnosed with ADHD, father with major depressive 
disorder and uncle of father with bipolar disorder. 
At the time of suicide attempt, he was on 36 mg/day 
MPH OROS monotherapy and had been using the 
medication in that dose for 1.5 years. He was 155 cm 
and 40 kg. He received no other medications, did 
not report depressive symptoms nor any alterations 
in mood, had no suicidal ideation prior to this 
suicide attempt. He had issues with anger 
management and experienced conflicts with his 
parents home. On the day of suicide attempt, he 
argued with his parents and took 15 tablets of 36 mg 
MPH-OROS (540 mg, in total) impulsively. Shortly 
after intake, he informed his parents and they all 
went to an emergency room of a state hospital. 
Within an hour of the suicide attempt, he was given 
active charcoal and 500 ml normal saline solution. 
On the way in ambulance and upon arrival at 
hospital, he was described to be hyperkinetic, talked 
too much but could not stay on one subject and 
seemed very distressed. He was described having 
motor jerks, had tingling sensations throughout his 
whole body, his heart raced, and felt restless. He did 
not have any alterations regarding his consciousness 
at any point or did not have any seizures. He was 
disoriented, had visual and tactile hallucinations, 
was slightly agitated and logorrheic so it was not 
possible to perform full psychiatric examination at 
that point. His body temperature was elevated 
(38.2ºC), along with heart rate (138/min) and blood 
pressure (145/92 mmHg). His blood tests at this 
time came back normal. Upon initial clinical 
stabilization, he was transfered to a children’s 
hospital to be observed and evaluated by a child 
and adolescent psychiatrist. Upon staying overnight 
being monitored, he was discharged the following 
day. His physical examination, laboratory tests, and 
cardiac monitorization were normal at discharge. 
He reported feeling thirsty a lot, experiencing 
conflicting emotions, not being able to fall asleep 
although he felt worn out. He was scheduled an 
appointment from the child psychiatry unit three 
days later. No physical or psychological symptoms 
related to MPH toxicity were reported in the follow 
up. 
DISCUSSION
This article presents the clinical picture of a 12 year 
old boy who attempted suicide by ingesting 15 
tablets of 36- mg MPH OROS (540 mg, in total). 
Toxicity symptoms in case of ingesting higher 
doses are similar to ones observed with receiving 
other sympatomimetic agents in high doses. These 
include headache, abnormal movements, rigidity, 
mood and behavior changes, hallucinations, 
hypertension, tachycardia, chest pain, vomiting7. 
Our case experienced most of these symptoms. 
 Reports of long-acting MPH toxicity are mainly 
limited to case reports in literature. Majority of 
methylphenidate overdoses have presented with 
moderate severity, but fatalities have been reported 
as well5,8. Toxic dose of MPH OROS preparates is 
not clearly known; but generally, doses above 2 
mg/kg are considered dangerous and need to be 
followed up in an emergency unit and require 
administration of active charcoal if the patient has 
arrived in proposed time limits, which would be 
within approximately 2-3 hours after ingestion7. 
Amount of intake in our case was 13.5 mg/kg which 
was considered to be a very high dose. As the case 
had initially arrived an hour after ingesting MPH, 
he was given active charcoal and started on fluid 
replacement for support. 
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 In many MPH overdose cases, serum MPH 
levels were assessed6,8; however it was not possible 
to evaluate this in our case which might be 
considered a limitation. On the other hand, there 
are studies that indicate that very similar to 
amphetamine toxicity, monitoring serum MPH 
concentrations provide limited clinical usefulness 
and is not recommended since serum MPH 
concentrations do not necessarily correlate with 
clinical picture5. Limited number of case reports 
exist with patients reported to have not needed 
further medical intervention and making full 
recovery8-11. 
 Although this case did not develop life 
threatening conditions that would require further 
medical assistance, given the family history of 
mood disorders and the case’s difficulties in anger 
management along with primary diagnosis as 
ADHD, there is a possibility that the clinical course 
might develop into further impulsive and risky 
behavior along with possible mood swings, and a 
risk for emerging comorbidities in the future 
including mood disorders, underlining the need 
for closer follow up. Even though this case report 
might suggest high doses of MPH-OROS could be 
tolerated well under fine clinical observation and 
management; more studies and clarification in this 
field would be required.
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